Multi-receptor stimulants and their medical uses

Modified GLP-1 analogues with specific amino acid sequences and fatty acid conjugations address the limitations of current GLP-1 polypeptides by enhancing stability and efficacy for treating non-insulin-dependent diabetes and obesity, offering superior blood sugar control and weight reduction.

JP7577678B2Active Publication Date: 2024-11-05JIANGSU HANSOH PHARMA CO LTD +1
View PDF 7 Cites 0 Cited by

Patent Information

Application Number
JP2021558700
Authority / Receiving Office
JP · JP
Patent Type
Patents
Current Assignee / Owner
Priority Date
2019-11-15
Filing Date
2020-04-10
Publication Date
2024-11-05
Estimated Expiration
2040-04-10

AI Technical Summary

Technical Problem

Current GLP-1 polypeptides and derivatives used for treating non-insulin-dependent diabetes and obesity-related diseases have limited efficacy due to rapid degradation in the body and significant side effects, such as nausea, vomiting, and increased risk of pancreatitis, necessitating the development of more stable and effective dual stimulants for GLP-1 and GIP receptors.

Method used

Development of GLP-1 analogues with specific amino acid sequences and modifications, including fatty acid conjugations, to enhance stability and efficacy, providing stronger blood sugar control and weight reduction effects.

Benefits of technology

The modified GLP-1 analogues demonstrate improved stability in plasma, reduced side effects, and enhanced metabolic activity, effectively lowering blood glucose and body weight in diabetic and obese models.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 0007577678000001
    Figure 0007577678000001
  • Figure 0007577678000002
    Figure 0007577678000002
  • Figure 0007577678000003
    Figure 0007577678000003
Patent Text Reader

Abstract

The present invention relates to a series of pharmaceutical compositions containing polypeptide dual stimulatory compounds and pharmaceutically acceptable salts thereof, which have dual stimulatory effects on the human glucagon-like peptide-1 (GLP-1) receptor and the human glucose-dependent insulinotropic polypeptide (GIP) receptor, and can be used to treat non-insulin-dependent diabetes mellitus, insulin-dependent diabetes mellitus, obesity, and other related disorders.
Need to check novelty before this filing date? Find Prior Art

Description

[Technical field]

[0001] The present invention belongs to the field of biomedicine, and specifically relates to stimulating agents having stimulatory effects on both the human glucagon-like peptide 1 (GLP-1) receptor and the human glucose-dependent insulinotropic polypeptide (GIP) receptor, and their use for treating metabolic disorders such as non-insulin-dependent diabetes mellitus, insulin-dependent diabetes mellitus, and obesity-related disorders. [Background technology]

[0002] Diabetes mellitus, a metabolic disease, is the dysregulation of glucose, protein, and lipid metabolism in vivo due to insufficient insulin secretion in vivo. Based on the differences in its pathological mechanisms, diabetes is mainly classified into insulin-dependent diabetes mellitus (type 1 diabetes) and non-insulin-dependent diabetes mellitus (type 2 diabetes). Among them, non-insulin-dependent diabetes mellitus affects 90-95% of diabetic patients worldwide. Non-insulin-dependent diabetes mellitus is a long-term chronic metabolic disease caused by impaired pancreatic beta cell function and long-term insulin resistance, characterized by reduced insulin levels in vivo and high concentrations of glucose in plasma. As shown in studies, non-insulin-dependent diabetes mellitus is associated with the development of various high-risk diseases in patients, often leading to diseases such as cardiovascular disease, renal failure, blindness, and amputation.

[0003] One of the main causes of non-insulin-dependent diabetes mellitus is obesity. Obesity is defined as an excessive or abnormal accumulation of fat in the body that impairs human health. Using the human body mass index (BMI), obesity is defined as a BMI index of 30 kg / m 2 The development of obesity significantly increases the risk of cardiovascular disease, diabetes, musculoskeletal disorders, and certain cancers. An increase in body mass index also increases the risk of certain non-communicable diseases.

[0004] Because diabetes and its complications bring about a huge number of patients and a significant economic burden, the development of safe and effective drugs to treat diabetes has always been one of the focus areas of many research institutes and pharmaceutical companies. Currently, approved diabetes drugs mainly include chemically synthesized small molecule oral hypoglycemic agents such as biguanides, sulfonyls, insulin sensitizers, and α-glycosides, and injectable hypoglycemic agents such as biosynthesized recombinant insulin and its derivatives. Although these drugs can effectively control plasma glucose levels in diabetic patients in clinical practice, long-term use often involves side effects such as weight gain, which results in increased risk of potential cardiovascular disease and reduced patient compliance. Considering the potential pathological relationship between diabetes and obesity and the potential risks of obesity-related complications, developing drugs that can effectively control blood glucose and properly reduce the weight of diabetic patients for the purpose of effective treatment of diabetes and reducing the risk of potential complications is very important in many ways, and is therefore a better direction for clinical research.

[0005] Glucagon-like peptide 1 (GLP-1) is a gastrointestinal regulatory polypeptide containing 30 or 31 amino acid residues. GLP-1 secretion is mainly regulated by L-cells in the small intestine in response to nutrient absorption and fluctuations in blood glucose levels in vivo. After a meal, L-cells in the small intestine secrete large amounts of GLP-1 to enhance the endocrine function of the pancreas. GLP-1 polypeptide mainly achieves its physiological function in vivo of controlling blood glucose and reducing appetite by activating GLP-1 receptors distributed on the surface of the cell membrane. The main mechanism by which GLP-1 controls blood glucose levels in vivo is to activate GLP-1 receptors distributed on pancreatic β cells to promote insulin biosynthesis and secretion. At the same time, when blood glucose levels in vivo are high, GLP-1 polypeptide can also inhibit glucagon secretion, gastric emptying, and food intake, and promote the in vivo degradation of glucose through certain nervous system effects. Notably, the physiological function of GLP-1 polypeptide to promote insulin secretion is highly controlled by the concentration of plasma glucose. Therefore, GLP-1 polypeptides do not cause severe and long-term hypoglycemia compared to other diabetes treatments. Also, as reported in the literature, GLP-1 polypeptides and their analogs can directly promote the growth, differentiation, and proliferation of β cells in experimental animals, and exhibit physiological effects such as protecting pancreatic islets and delaying the progression of diabetes, thereby inhibiting β cell apoptosis. GLP-1 polypeptides can also inhibit the secretion of gastrin and gastric acid stimulated by food intake. This characteristic means that GLP-1 polypeptides also play a physiological role in the prevention of peptic ulcers. GLP-1 polypeptides can also activate GLP-1 receptors distributed in the central nervous system (brain) to achieve the physiological effects of increasing satiety, reducing food intake, and maintaining or reducing body weight. Therefore, due to the broad mechanism of action and physiological functions of GLP-1 polypeptides and their analogs, GLP-1 polypeptides are ideal drugs for treating non-insulin-dependent diabetes mellitus and obesity diabetes.

[0006] The physiological functions of GLP-1 polypeptide in controlling blood glucose and reducing body weight have brought hope for the treatment of non-insulin-dependent diabetes mellitus / obesity diabetes. However, native human GLP-1 is susceptible to degradation by dipeptide-based peptide hydrolase IV (DPP-IV) in vivo, leading to low efficacy and a half-life of only 1-2 minutes in the human body. Faced with such difficulties, the pharmaceutical industry has constructed long-acting GLP-1 analogs and their derivatives by site-directed amino acid mutations at restriction sites, fatty acid modifications of the polypeptide backbone, and conjugation of GLP-1 polypeptide to various proteins / polymers. Long-acting GLP-1 analogs available on the market and widely used in clinical practice include exenatide (subcutaneous injection, bid.), liraglutide (subcutaneous injection, qd.), and dulaglutide and semaglutide (subcutaneous injection, qw.), etc.

[0007] Clinically, the side effects of GLP-1 polypeptide and its derivatives are mainly caused by gastrointestinal tract, such as nausea, vomiting and diarrhea.In addition, it has been found that GLP-1 polypeptide and its derivatives also cause palpitations in subjects and, under certain circumstances, increase the risk of pancreatitis in patients.Therefore, due to its side effects, the dosage of GLP-1 polypeptide and its derivatives is limited, and in clinical use, it cannot achieve total blood glucose control and weight loss in patients.

[0008] Both glucose-dependent insulinotropic polypeptide (GIP) and GLP-1 polypeptide belong to the type of incretins that play a physiologically important role in the metabolism of blood glucose in vivo. GIP is mainly composed of 42 amino acid residues in vivo and is secreted by K cells present in the duodenum next to the jejunum in response to blood glucose levels. GIP polypeptide exerts its physiological effects by binding to GIP receptors distributed in pancreatic β cells, adipose tissue, and the central nervous system. Like GLP-1 polypeptide, GIP polypeptide stimulates pancreatic β cells to secrete insulin, thereby lowering blood glucose levels, protecting pancreatic β cells, and controlling glucose metabolism in vivo. The physiological functions of GIP polypeptide also include activating GIP receptors in adipose tissue, thereby promoting fat metabolism. Interestingly, intracerebroventricular injection of GIP polypeptide in mice can reduce food intake and body weight in the test animals. This seems to indicate that GIP polypeptide also has a specific physiological function in reducing body weight. As shown in the study, the incretin function of GIP polypeptide in patients with non-insulin-dependent diabetes mellitus is significantly reduced, leading to the absence or loss of incretin effect in the patients. As shown in the study, it was observed that in these diabetic patients, when blood glucose levels return to normal, the inhibition of GIP polypeptide is significantly weakened.

[0009] Therefore, there is a need in the clinic for a method of treating non-insulin-dependent diabetes with GIP polypeptides, and for a clinically effective hypoglycemic agent for restoring the tolerance of non-insulin-dependent diabetes patients to GIP polypeptides, which is further combined with the incretin effect of GIP polypeptides to obtain a stronger clinical hypoglycemic effect. Therefore, compared with many GLP-1 receptor stimulator polypeptides in the art, the object of the present invention is to provide derivatives of GLP-1 analogs that have stimulatory activity on human GIP receptors and have dual stimulatory effects on both human GLP-1 receptors and human GIP receptors. In addition, certain compounds of the present invention have stronger effects on lowering blood glucose and reducing body weight than GLP-1 receptor stimulators in the art. Finally, certain compounds of the present invention have very high stability in plasma and pharmacokinetic properties that support administration by subcutaneous injection once a week in humans. Summary of the Invention

[0010] It is an object of the present invention to provide a GLP-1 analogue having the general formula (I) or a pharma- ceutically acceptable salt thereof: X1-X2-Glu-Gly-Thr-Phe-Thr-Ser-Asp-X 10 -Ser-X 12 -Tyr-Leu-X 15 -X 16 -X 17 -X 18 -X 19 -X 20 -Glu-Phe-X 23 -X 24 -Trp-Leu-X 27 -X 28 -X 29 -X 30 -Pro-Ser-Ser-Gly-Ala-Pro-Pro-Pro-Ser-X 40 (I) During the ceremony, X1, X2, X 10 , X 12 , X 15 , X 16 , X 17, X 18 , X 19 , X 20 , X 27 , X 28 , X 29 , and X 30 are independently selected from any natural or unnatural amino acid, or peptide fragments thereof; X 40 is selected from any natural or unnatural amino acid, or a peptide fragment thereof, or X 40 does not exist.

[0011] The present invention also relates to a technical solution comprising a GLP-1 analogue having general formula (I) or a pharma- ceutically acceptable salt thereof, characterized in that the GLP-1 analogue is modified at both ends as follows: R1-X1-X2-Glu-Gly-Thr-Phe-Thr-Ser-Asp-X 10 -Ser-X 12 -Tyr-Leu-X 15 -X 16 -X 17 -X 18 -X 19 -X 20 -Glu-Phe-X 23 -X 24 -Trp-Leu-X 27 -X 28 -X 29 -X 30 -Pro-Ser-Ser-Gly-Ala-Pro-Pro-Pro-Ser-X 40 -R2 (II) During the ceremony, R1 is H, alkyl, acetyl, formyl, benzoyl, trifluoroacetyl, or pGlu; R2 is -NH2 or -OH; X1, X2, X 10 , X 12 , X 15 , X 16 , X 17 , X 18 , X 19 , X 20 , X 27, X 28 , X 29 , and X 30 are independently selected from any natural or unnatural amino acid, or peptide fragments thereof; X 40 is selected from any natural or unnatural amino acid, or a peptide fragment thereof, or X 40 does not exist.

[0012] The present invention also relates to a preferred technical solution comprising a GLP-1 analogue having the general formula (I) or a pharma- ceutically acceptable salt thereof, wherein X1 is selected from the amino acid residues Tyr or His; X2 is selected from the amino acid residues Aib or D-Ala; 10 is selected from the amino acid residues Val or Tyr; 12 is selected from the amino acid residues Ser or Ile; 15 is selected from the amino acid residues Asp or Glu; 16 is selected from the amino acid residues Glu, Gly, Lys, or Aib; 17 is selected from the amino acid residues Glu, Ile, or Gln; 18 is selected from the amino acid residues Ala, Aib, or His; 19 is selected from the amino acid residues Ala, Aib, or Gln; 20 is selected from the amino acid residues Gln, Glu, Lys, or Y1; 23 is selected from the amino acid residues Ile or Val; 24 is selected from the amino acid residues Ala, Asn, or Gln; 27 is selected from the amino acid residues Val, Ile, or Leu; 28 is selected from the amino acid residues Arg or Ala; 29 is selected from the amino acid residues Gly or Gln; 30 is selected from the amino acid residues Gly, Lys, or Y1; 40 is selected from the amino acid residues Lys or Y1, or is absent.

[0013] The present invention also relates to a preferred technical solution comprising a GLP-1 analogue having the general formula (I) or a pharma- ceutically acceptable salt thereof, wherein X1 is selected from the amino acid residues Tyr or His; X2 is selected from the amino acid residues Aib or D-Ala; 10 is selected from the amino acid residues Val or Tyr; 12 is selected from the amino acid residues Ser or Ile; 15 is selected from the amino acid residues Asp or Glu; 16 is selected from the amino acid residues Glu, Gly, Lys, or Aib; 17 is selected from the amino acid residues Glu, Ile, or Gln; 18 is selected from the amino acid residues Ala, Aib, or His; 19 is selected from the amino acid residues Ala, Aib, or Gln; 20 is selected from the amino acid residues Gln, Glu, Lys, or Y1; 23 is selected from the amino acid residues Ile or Val; 24 is selected from the amino acid residues Ala, Asn, or Gln; 27 is selected from the amino acid residues Val or Leu; 28 is selected from the amino acid residues Arg or Ala; 29 is selected from the amino acid residues Gly or Gln; 30 is selected from the amino acid residues Gly, Lys, or Y1; 40 is selected from the amino acid residues Lys or Y1, or absent; Y1 is a group having a side chain of the formula {[2-(2-amino-ethoxy)-ethoxy]-acetyl} a -(y-Glu) b -CO-(CH2) c It is a Lys, Orn, Dap, Dab, or Cys residue conjugated to a substituent represented by -COOH (wherein a is an integer of 1 to 3; b is an integer of 1 to 2; c is an integer of 10 to 30).

[0014] The present invention also relates to a preferred technical solution comprising a GLP-1 analogue having the general formula (I) or a pharma- ceutically acceptable salt thereof, wherein X1 is selected from the amino acid residue Tyr; X2 is selected from the amino acid residue Aib; and X 10 is selected from the amino acid residue Tyr; 12 is selected from the amino acid residue Ile; 15 is selected from the amino acid residues Asp or Glu; 16 is selected from the amino acid residues Lys or Aib; 17 is selected from the amino acid residues Glu or Ile; 18 is selected from the amino acid residues Ala or Aib; 19 is selected from the amino acid residues Ala or Gln; 20 is selected from the amino acid residues Gln, Lys, or Y1; 23 is selected from the amino acid residue Val; 24 is selected from the amino acid residues Asn or Gln; 27 is selected from the amino acid residue Leu; 28 is selected from the amino acid residue Ala; 29 is selected from the amino acid residues Gly or Gln; 30 is selected from the amino acid residues Gly, Lys, or Y1; 40 is selected from the amino acid residues Lys or Y1, or absent; Y1 is a group having a side chain of the formula {[2-(2-amino-ethoxy)-ethoxy]-acetyl} a -(y-Glu) b -CO-(CH2) c It is a Lys, Orn, Dap, Dab, or Cys residue conjugated to a substituent represented by -COOH (wherein a is an integer of 1 to 3; b is an integer of 1 to 2; c is an integer of 10 to 30).

[0015] The present invention also relates to a preferred technical solution comprising a GLP-1 analogue having the general formula (I) or a pharma- ceutically acceptable salt thereof, wherein X1 is selected from the amino acid residue Tyr; X2 is selected from the amino acid residue Aib; 10 is selected from the amino acid residue Tyr;12 is selected from the amino acid residue Ile; 15 is selected from the amino acid residue Glu; 16 is selected from the amino acid residue Lys; 17 is selected from the amino acid residue Glu; 18 is selected from the amino acid residues Ala or Aib; 19 is selected from the amino acid residue Ala; 20 is selected from the amino acid residues Gln, Lys, or Y1; 23 is selected from the amino acid residue Val; 24 is selected from the amino acid residue Asn; 27 is selected from the amino acid residue Leu; 28 is selected from the amino acid residue Ala; 29 is selected from the amino acid residue Gly; 30 is selected from the amino acid residues Gly, Lys, or Y1; 40 is selected from the amino acid residues Lys or Y1, or is absent.

[0016] The present invention also relates to a preferred technical solution comprising a GLP-1 analogue having the general formula (I) or a pharma- ceutically acceptable salt thereof, wherein X1 is selected from the amino acid residue Tyr; X2 is selected from the amino acid residue Aib; 10 is selected from the amino acid residue Tyr; 12 is selected from the amino acid residue Ile; 15 is selected from the amino acid residue Glu; 16 is selected from the amino acid residue Lys; 17 is selected from the amino acid residue Ile; 18 is selected from the amino acid residues Ala or Aib; 19 is selected from the amino acid residue Ala; 20 is selected from the amino acid residues Gln, Lys, or Y1; 23 is selected from the amino acid residue Val; 24 is selected from the amino acid residue Asn; 27 is selected from the amino acid residue Leu;28 is selected from the amino acid residue Ala; 29 is selected from the amino acid residue Gly; 30 is selected from the amino acid residues Gly, Lys, or Y1; 40 is selected from the amino acid residues Lys or Y1, or is absent.

[0017] The present invention also relates to a preferred technical solution comprising a GLP-1 analogue having the general formula (I) or a pharma- ceutically acceptable salt thereof, wherein X1 is selected from the amino acid residue Tyr; X2 is selected from the amino acid residue Aib; 10 is selected from the amino acid residue Tyr; 12 is selected from the amino acid residue Ile; 15 is selected from the amino acid residue Glu; 16 is selected from the amino acid residue Lys; 17 is selected from the amino acid residues Glu or Ile; 18 is selected from the amino acid residue Ala; 19 is selected from the amino acid residue Ala; 20 is selected from the amino acid residues Gln, Lys, or Y1; 23 is selected from the amino acid residue Val; 24 is selected from the amino acid residue Asn; 27 is selected from the amino acid residue Leu; 28 is selected from the amino acid residue Ala; 29 is selected from the amino acid residue Gly; 30 is selected from the amino acid residues Gly, Lys, or Y1; 40 is selected from the amino acid residues Lys or Y1, or is absent.

[0018] The present invention also relates to a preferred technical solution comprising a GLP-1 analogue having the general formula (I) or a pharma- ceutically acceptable salt thereof, wherein X1 is selected from the amino acid residue Tyr; X2 is selected from the amino acid residue Aib; 10 is selected from the amino acid residue Tyr; 12is selected from the amino acid residue Ile; 15 is selected from the amino acid residue Glu; 16 is selected from the amino acid residue Lys; 17 is selected from the amino acid residues Glu or Ile; 18 is selected from the amino acid residues Aib; 19 is selected from the amino acid residue Ala; 20 is selected from the amino acid residues Gln, Lys, or Y1; 23 is selected from the amino acid residue Val; 24 is selected from the amino acid residue Asn; 27 is selected from the amino acid residue Leu; 28 is selected from the amino acid residue Ala; 29 is selected from the amino acid residue Gly; 30 is selected from the amino acid residues Gly, Lys, or Y1; 40 is selected from the amino acid residues Lys or Y1, or is absent.

[0019] The present invention also relates to a preferred technical solution comprising a GLP-1 analogue having the general formula (I) or a pharma- ceutically acceptable salt thereof, wherein X1 is selected from the amino acid residue Tyr; X2 is selected from the amino acid residue Aib; 10 is selected from the amino acid residue Tyr; 12 is selected from the amino acid residue Ile; 15 is selected from the amino acid residue Glu; 16 is selected from the amino acid residue Lys; 17 is selected from the amino acid residues Glu or Ile; 18 is selected from the amino acid residues Ala or Aib; 19 is selected from the amino acid residue Ala; 20 is selected from the amino acid residue Gln; 23 is selected from the amino acid residue Val; 24 is selected from the amino acid residue Asn; 27 is selected from the amino acid residue Leu; 28is selected from the amino acid residue Ala; 29 is selected from the amino acid residue Gly; 30 is selected from the amino acid residues Gly, Lys, or Y1; 40 is selected from the amino acid residues Lys or Y1, or is absent.

[0020] The present invention also relates to a preferred technical solution comprising a GLP-1 analogue having the general formula (I) or a pharma- ceutically acceptable salt thereof, wherein X1 is selected from the amino acid residue Tyr; X2 is selected from the amino acid residue Aib; 10 is selected from the amino acid residue Tyr; 12 is selected from the amino acid residue Ile; 15 is selected from the amino acid residue Glu; 16 is selected from the amino acid residue Lys; 17 is selected from the amino acid residues Glu or Ile; 18 is selected from the amino acid residues Ala or Aib; 19 is selected from the amino acid residue Ala; 20 is selected from the amino acid residue Lys; 23 is selected from the amino acid residue Val; 24 is selected from the amino acid residue Asn; 27 is selected from the amino acid residue Leu; 28 is selected from the amino acid residue Ala; 29 is selected from the amino acid residue Gly; 30 is selected from the amino acid residues Gly, Lys, or Y1; 40 is selected from the amino acid residues Lys or Y1, or is absent.

[0021] The present invention also relates to a preferred technical solution comprising a GLP-1 analogue having the general formula (I) or a pharma- ceutically acceptable salt thereof, wherein X1 is selected from the amino acid residue Tyr; X2 is selected from the amino acid residue Aib; 10 is selected from the amino acid residue Tyr; 12 is selected from the amino acid residue Ile;15 is selected from the amino acid residue Glu; 16 is selected from the amino acid residue Lys; 17 is selected from the amino acid residues Glu or Ile; 18 is selected from the amino acid residues Ala or Aib; 19 is selected from the amino acid residue Ala; 20 is selected from Y1;X 23 is selected from the amino acid residue Val; 24 is selected from the amino acid residue Asn; 27 is selected from the amino acid residue Leu; 28 is selected from the amino acid residue Ala; 29 is selected from the amino acid residue Gly; 30 is selected from the amino acid residues Gly, Lys, or Y1; 40 is selected from the amino acid residues Lys or Y1, or is absent.

[0022] The present invention also relates to a preferred technical solution comprising a GLP-1 analogue having the general formula (I) or a pharma- ceutically acceptable salt thereof, wherein X1 is an amino acid residue Tyr; X2 is an amino acid residue Aib; and X 10 is the amino acid residue Tyr; 12 is the amino acid residue Ile; 15 is the amino acid residue Glu; 16 is the amino acid residue Lys; X 17 is selected from the amino acid residues Glu or Ile; 18 is selected from the amino acid residues Ala or Aib; 19 is the amino acid residue Ala; 20 is Gln;X 23 is the amino acid residue Val; 24 is the amino acid residue Asn; 27 is the amino acid residue Leu; X 28 is the amino acid residue Ala; 29 is the amino acid residue Gly; 30is selected from the amino acid residues Gly, Lys, or Y1; 40 is selected from the amino acid residues Lys or Y1, or is absent.

[0023] The present invention also relates to a preferred technical solution comprising a GLP-1 analogue having the general formula (I) or a pharma- ceutical acceptable salt thereof, 20 , X 30 , and X 40 are each independently selected from Y1, wherein Y1 is a group having a side chain of the formula {[2-(2-amino-ethoxy)-ethoxy]-acetyl} a -(y-Glu) b -CO-(CH2) c It is a Lys, Orn, Dap, Dab, or Cys residue conjugated to a substituent represented by -COOH (wherein a is an integer of 1 to 3; b is an integer of 1 to 2; c is an integer of 10 to 30).

[0024] The present invention also relates to a preferred technical solution comprising a GLP-1 analogue having general formula (I) or a pharma- ceutically acceptable salt thereof, wherein in the definition of Y1, a is 2; b is 1 or 2; and c is 16 to 20.

[0025] The present invention also relates to a preferred technical solution comprising a GLP-1 analogue having general formula (I) or a pharma- ceutically acceptable salt thereof, wherein in the definition of Y1, a is 2; b is 1 or 2; and c is 16, 18, or 20.

[0026] The present invention also relates to a preferred technical solution comprising a GLP-1 analogue having the general formula (I) or a pharma- ceutical acceptable salt thereof, 40 is selected from Y1, wherein the side chain is of the formula {[2-(2-amino-ethoxy)-ethoxy]-acetyl} a -(y-Glu) b -CO-(CH2) c is a Lys residue conjugated to a substituent represented by --COOH; a is 2; b is 1 or 2; and c is 16 or 18.

[0027] The present invention also relates to a preferred technical solution comprising a GLP-1 analogue having general formula (I) or a pharma- ceutically acceptable salt thereof, wherein said Y1 is covalently attached to a fatty acid by formation of an amide bond via the side chain amino group of Lys.

[0028] The present invention also relates to a preferred technical solution comprising a GLP-1 analogue having general formula (I) or a pharma- ceutically acceptable salt thereof, wherein Y1 is K(-OEG-OEG-yGlu-C18-OH) or K(-OEG-OEG-yGlu-C20-OH), which is represented by the chemical formula comprising the following structure: JPEG0007577678000001.jpg54133

[0029] The present invention also relates to a preferred technical solution comprising a GLP-1 analogue having general formula (I) or a pharma- ceutically acceptable salt thereof, wherein said -OEG-OEG-yGlu-C18-OH or -OEG-OEG-yGlu-C20-OH group is represented as a chemical formula comprising the following structure: JPEG0007577678000002.jpg32137

[0030] The present invention also relates to a preferred technical solution comprising a GLP-1 analogue having general formula (I) or a pharma- ceutically acceptable salt thereof, wherein said Y1 is covalently linked to a fatty acid by an amide bond via the ε-amino group of the C-terminal Lys, and the α-amino group of the C-terminal Lys is linked to a peptide chain.

[0031] The present invention also relates to a preferred technical solution comprising a GLP-1 analogue having general formula (I) or a pharma- ceutically acceptable salt thereof, characterized in that it is selected from the following compounds Nos. 1 to 83: JPEG0007577678000003.jpg211137JPEG0007577678000004.jpg210137JPEG0007577678000005.jpg125137

[0032] The present invention also relates to a preferred technical solution comprising: 1) a pharmaceutical composition comprising a therapeutic amount of a GLP-1 analog having general formula (I) or a pharma- ceutical acceptable salt thereof; and 2) a pharma-ceutical acceptable excipient or pharmaceutical carrier.

[0033] The present invention also relates to a preferred technical solution comprising the use of a GLP-1 analog having general formula (I) or a pharma- ceutical acceptable salt thereof and a composition having general formula (I) in the manufacture of a medicament for treating non-insulin-dependent diabetes mellitus, insulin-dependent diabetes mellitus, or obesity.

[0034] The present invention also relates to a preferred technical solution comprising a GLP-1 analogue having general formula (I) or a pharma- ceutically acceptable salt thereof, administered simultaneously, separately or sequentially in combination with one or more agents selected from the group consisting of metformin, thiazolidinediones, sulfonylureas, dipeptidyl peptide hydrolase inhibitors, and sodium glucose transporters.

[0035] The present invention also relates to a preferred technical solution comprising a GLP-1 analogue having general formula (I) or a pharma- ceutically acceptable salt thereof, or a composition having general formula (I), administered simultaneously, separately or sequentially in combination with one or more agents selected from the group consisting of metformin, thiazolidinedione, sulfonylurea, dipeptidyl peptide hydrolase inhibitors, and sodium glucose transporters.

[0036] In another embodiment, the present invention provides polypeptide compounds as described above and pharma- ceutically acceptable salts thereof.

[0037] The dual stimulatory compounds of polypeptides and their derivatives provided by the present invention belong to amphoteric compounds, which can react with acidic or basic compounds to form salts using techniques well known to those skilled in the art. Acids commonly used to form acid addition salts are hydrochloric acid, hydrobromic acid, hydroiodic acid, sulfuric acid, phosphoric acid, p-toluenesulfonic acid, methanesulfonic acid, oxalic acid, p-bromophenylsulfonic acid, carbonic acid, succinic acid, citric acid, benzoic acid, or acetic acid. Salts include sulfate, pyrosulfate, trifluoroacetate, sulfite, bisulfite, phosphate, hydrogen phosphate, dihydrogen phosphate, metaphosphate, pyrophosphate, hydrochloride, bromide, iodide, acetate, propionate, caprylate, acrylate, formate, isobutyrate, caproate, heptanoate, propiolate, oxalate, malonate, succinate, suberate, fumarate, maleate, butyne-1,4-dioate, hexyne-1,6-dioate, hexyne-1,7-dioate, hexyne-1,8-dioate, hexyne-1,9-dioate, hexyne-2,10-dioate, hexyne-2,11-dioate, hexyne-2,2-dioate, hexyne-2,3-dioate, hexyne-2,4-dioate, hexyne-2,5-dioate, hexyne-2,6-dioate, hexyne-2,7-dioate, hexyne-2,8-dioate, hexyne-2,9-dioate, hexyne-2,10-dioate, hexyne-2,11-dioate, hexyne-2,12-dioate, hexyne-2,13-dioate, hexyne-2,14-dioate, hexyne-2,15-dioate, hexyne-2,2-dioate, hexyne-2,2-dioate, hexyne-2,3-dioate, hexyne-2,4-dioate, hexyne-2,5-dioate, hexyne-2,6-dioate, hexyne-2,7-dioate, hexyne-2,8-dioate, hexyne-2,15- The salts include dioate, benzoate, chlorobenzoate, methylbenzoate, dinitrobenzoate, hydroxybenzoate, methoxybenzoate, phenylacetate, phenylpropionate, phenylbutyrate, citrate, lactate, γ-hydroxybutyrate, glycolate, tartrate, mesylate, propanesulfonate, naphthalene-1-sulfonate, naphthalene-2-sulfonate, or mandelate, and preferably trifluoroacetate. Alkaline substances can also form salts with the polypeptide compounds and their derivatives provided by the present invention. These alkaline substances include hydroxides of ammonium, alkali metals, or alkaline earth metals, as well as carbonates and bicarbonates, typically sodium hydroxide, potassium hydroxide, ammonium hydroxide, sodium carbonate, and potassium carbonate.

[0038] The pharmaceutical composition comprising the polypeptide dual stimulatory compound according to the present invention can be used to treat patients in need of such treatment by parenteral administration. Parenteral administration can be selected from subcutaneous injection, intramuscular injection, or intravenous injection. The polypeptide dual stimulatory compound of the present invention can also be administered via a transdermal route, such as transdermally administered via a patch, which can be selected as an iontophoretic patch; or can be administered via a transmucosal route.

[0039] The polypeptide compounds and their derivatives provided by the present invention are applied to solid-phase synthesis. The α-amino group of the amino acid derivatives used in the synthesis process is protected with Fmoc (fluorenylformylcarbonyl) group. Based on the difference in functional groups, the protecting groups used for the side chains of amino acids can be selected from the group consisting of: cysteine ​​side chain sulfhydryl, glutamine side chain amino, and histidine side chain imidazolyl are protected with Trt (triphenylmethyl); arginine side chain guanidyl is protected with Pbf (2,2,4,6,7-pentamethyldihydrobenzofuran-5-sulfonyl); tryptophan side chain indolyl and lysine side chain amino are protected with Boc (tert-butoxycarbonyl); and threonine side chain hydroxyl, tyrosine side chain phenol group, and serine side chain hydroxyl are protected with t-Bu (tert-butyl). In the synthesis process, the carboxyl group of the C-terminal amino acid residue of the polypeptide is first condensed to a polymer-insoluble Rink-Amide ChemMatrix resin in the form of an amide bond, then the Fmoc protecting group is removed from the α-amino group using a solution of N,N-dimethylformamide (DMF) containing 20% ​​piperidine, and the solid support is condensed with an excess of the next amino acid derivative in the sequence to form an amide bond to extend the peptide chain. The procedure of condensation → washing → deprotection → washing → next round of amino acid condensation is repeated until the desired length of the polypeptide chain to be synthesized is obtained, and finally the polypeptide is cleaved from the solid support by reacting the resin with a mixture of trifluoroacetic acid:water:triisopropylsilane (90:5:5, v:v:v), and then precipitated with frozen isopropyl ether to obtain a solid crude product of the polypeptide derivative. The solid crude product of the polypeptide is purified by dissolving it in a mixture of acetonitrile / water containing 0.1% trifluoroacetic acid and separating it on a C-18 reverse phase preparative chromatography column to obtain a high purity product of the polypeptide and its derivatives.

[0040] Unless stated to the contrary, terms used in the specification and claims have the following meanings.

[0041] The amino acid sequences of the present invention include the one-letter or three-letter codes of the 20 standard amino acids. Unless otherwise specified, the preferred configuration of all amino acid residues in the present invention is the L-configuration. Also, Aib refers to α-aminoisobutyric acid, and D-Ala refers to D-alanine.

[0042] The term "stimulant" is defined as a substance that activates the receptor type being discussed. As used in the context of the present invention, the term "GLP-1 / GIP dual agonist" refers to a substance or ligand that can activate both the GLP-1 receptor and the GIP receptor. In the present invention, the term "treatment" includes inhibiting, slowing, stopping, or reversing existing symptoms, or the progression or severity of a disease.

[0043] "Natural amino acid" refers to the 20 conventional amino acids (i.e., alanine (A), cysteine ​​(C), aspartic acid (D), glutamic acid (E), phenylalanine (F), glycine (G), histidine (H), isoleucine (I), lysine (K), leucine (L), methionine (M), asparagine (N), proline (P), glutamine (Q), arginine (R), serine (S), threonine (T), valine (V), tryptophan (W), and tyrosine (Y)).

[0044] "Unnatural amino acids" refer to amino acids that are not naturally encoded or found in the genetic code of any organism. They can be, for example, purely synthetic compounds. Examples of unnatural amino acids include hydroxyproline, γ-carboxyglutamic acid, O-phosphoserine, azetidine carboxylic acid, 2-aminoadipate, 3-aminoadipate, β-alanine, aminopropionic acid, 2-aminobutyric acid, 4-aminobutyric acid, 6-aminocaproic acid, 2-aminoheptanoic acid, 2-aminoisobutyric acid, 3-aminoisobutyric acid, 2-aminopimelic acid, tert-butylglycine, 2,4-diaminoisobutyric acid (Dap), desmosine, 2,2'-diaminopimelic acid, 2,3-diaminopropionic acid (Dab), N-ethylglycine, N These include, but are not limited to, N-methylglycine, N-ethylasparagine, homoproline, hydroxylysine, allohydroxylysine, 3-hydroxyproline, 4-hydroxyproline, isodesmosine, alloisoleucine, N-methylalanine, N-methylglycine, N-methylisoleucine, N-methylpentylglycine, N-methylvaline, naphthalanine, norvaline, norleucine, ornithine (Orn), D-ornithine, D-arginine, p-aminophenylalanic acid, pentylglycine, pipecolic acid, and thioproline. Also included are natural or unnatural amino acids that have been chemically modified at the C-terminal carboxyl group, the N-terminal amino group, and / or side chain functional groups.

[0045] The term "alkyl" refers to alkyl groups, including saturated aliphatic alkyl groups, which are straight or branched chain groups containing from 1 to 20 carbon atoms, preferably alkyl groups containing from 1 to 8 carbon atoms, more preferably alkyl groups of from 1 to 6 carbon atoms, and most preferably alkyl groups of from 1 to 3 carbon atoms. Non-limiting examples include methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, tert-butyl, sec-butyl, n-pentyl, 1,1-dimethylpropyl, 1,2-dimethylpropyl, 2,2-dimethylpropyl, 1-ethylpropyl, 2-methylbutyl, 3-methylbutyl, n-hexyl, 1-ethyl-2-methylpropyl, 1,1,2-trimethylpropyl, 1,1-dimethylbutyl, 1,2-dimethylbutyl, 2,2-dimethylbutyl, 1,3-dimethylbutyl, 2-ethylbutyl, 2-methylpentyl, 3-methylpentyl, 4-methylpentyl, 2,3-dimethylbutyl, n-heptyl, 2-methylhexyl, 3-methylhexyl, 4-methylhexyl, 5-methylhexyl, Included are 2,3-dimethylpentyl, 2,4-dimethylpentyl, 2,2-dimethylpentyl, 3,3-dimethylpentyl, 2-ethylpentyl, 3-ethylpentyl, n-octyl, 2,3-dimethylhexyl, 2,4-dimethylhexyl, 2,5-dimethylhexyl, 2,2-dimethylhexyl, 3,3-dimethylhexyl, 4,4-dimethylhexyl, 2-ethylhexyl, 3-ethylhexyl, 4-ethylhexyl, 2-methyl-2-ethylpentyl, 2-methyl-3-ethylpentyl, n-nonyl, 2-methyl-2-ethylhexyl, 2-methyl-3-ethylhexyl, 2,2-diethylpentyl, n-decyl, 3,3-diethylhexyl, 2,2-diethylhexyl, and various branched isomers thereof.More preferred are lower alkyl groups containing 1 to 6 carbon atoms, non-limiting examples of which include methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, tert-butyl, sec-butyl, n-pentyl, 1,1-dimethylpropyl, 1,2-dimethylpropyl, 2,2-dimethylpropyl, 1-ethylpropyl, 2-methylbutyl, 3-methylbutyl, n-hexyl, 1-ethyl-2-methylpropyl, 1,1,2-trimethylpropyl, 1,1-dimethylbutyl, 1,2-dimethylbutyl, 2,2-dimethylbutyl, 1,3-dimethylbutyl, 2-ethylbutyl, 2-methylpentyl, 3-methylpentyl, 4-methylpentyl, 2,3-dimethylbutyl, and the like. The alkyl group may be substituted or unsubstituted. If substituted, the substituent may be substituted at any available point of attachment. The substituents are preferably one or more of groups independently selected from alkyl, alkenyl, alkynyl, alkoxy, alkylthio, alkylamino, halogen, sulfhydryl, hydroxyl, nitro, cyano, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, cycloalkyloxy, heterocycloalkoxy, cycloalkylthio, heterocycloalkylthio, oxo, carboxy, or carboxylate, and in the present invention are preferably methyl, ethyl, isopropyl, tert-butyl, haloalkyl, deuterated alkyl, alkoxy-substituted alkyl, and hydroxy-substituted alkyl.

[0046] "X is selected from A, B, or C", "X is selected from the group consisting of A, B, and C", "X is A, B, or C", "X is A, B, and C" and other terms all mean the same thing, i.e., "X may be any one or more of A, B, and C".

[0047] An amino acid "modification" as described in this patent refers to an amino acid substitution, addition, or deletion, including a substitution or addition of any of the 20 naturally occurring amino acids.

[0048] The term "native GLP-1" refers to a peptide comprising the human GLP-1(7-36 or 7-37) sequence, and the term "native GIP" refers to a peptide comprising the human GIP(1-42) sequence.

[0049] The terms "GLP-1" or "GIP" refer to native GLP-1 or native GIP, respectively, unless further explained.

[0050] An amino acid "substitution" as described in this patent refers to the replacement of an amino acid residue with a different amino acid residue.

[0051] The term "polyethylene glycol" or "PEG" exists as a linear or branched chain and is a cyclic amine. n It refers to a mixture of condensation polymers of ethylene oxide and water having the general formula: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 6

[0052] The terms "polyethylene glycol" or "PEG" are used with a numerical suffix to indicate its approximate average molecular weight. For example, PEG-5000 refers to polyethylene glycol having an average molecular weight of about 5000 daltons.

[0053] The term "PEGylation" or similar terms refers to the modification of a compound in its native state by attaching PEG chains to a peptide.

[0054] The term "PEGylated peptide" refers to a peptide having a PEG chain covalently attached to the peptide.

[0055] The term "fatty acid" refers to a carboxylic acid having a long fatty acid tail (chain) which may be saturated or unsaturated. In the present invention, fatty acid refers to a carboxylic acid having a straight or branched chain aliphatic group of 4 to 30 carbon atoms.

[0056] The general definition of a peptide described in this patent includes peptides having modified amino and carboxy termini, for example, an amino acid sequence designated as a natural amino acid also encompasses an amino acid chain containing a terminal carboxylic acid replaced with an amide group.

[0057] Any hydrogen atom described in the present invention can be replaced with its deuterium isotope, and any hydrogen atom in the exemplary compounds of the present invention can also be replaced with a deuterium atom.

[0058] "Optional" or "optionally" means that the event or circumstance following the term may occur, but does not necessarily occur, and the description includes cases where the event or circumstance occurs and cases where it does not occur. For example, "a heterocyclic group optionally substituted with an alkyl group" means that an alkyl group can be present (but is not necessarily), and the description includes cases where the heterocyclic group is substituted with an alkyl group and cases where the heterocyclic group is not substituted with an alkyl group.

[0059] "Substituted" refers to one or more hydrogen atoms in a group, preferably up to 5, more preferably 1 to 3 hydrogen atoms, independently replaced by a corresponding number of substituents. It is clear that the substituents are located only at possible chemical positions, and the skilled artisan can determine (by experiment or theory) possible or impossible substitutions without undue effort. For example, it may be unstable for an amino group or a hydroxyl group with free hydrogen to be bonded to a carbon atom with an unsaturated bond (e.g., olefinic).

[0060] A "pharmaceutical composition" refers to a mixture containing one or more compounds described herein, or physiologically / pharmaceutical acceptable salts or prodrugs thereof, and other chemical components, such as physiologically / pharmaceutical acceptable carriers and excipients. The purpose of the pharmaceutical composition is to facilitate administration to an organism and facilitate absorption of the active ingredients, thereby exerting a biological effect.

[0061] "Pharmaceutically acceptable salt" refers to a salt of a compound of the present invention that is safe and effective when administered to a mammal in vivo and possesses the expected biological activity. EXAMPLES

[0062] This specification provides the following specific embodiments to describe the present invention in more detail, but the technical solutions of the present invention are not limited to these embodiments.

[0063] 1. Experimental Reagents JPEG0007577678000006.jpg88131

[0064] 2. Experimental Equipment JPEG0007577678000007.jpg35137

[0065] 3. Specific Experimental Scheme 3.1 Chemical synthesis of polypeptide-based compound 1 3.1.1 Conjugation of Fmoc-L-Lys(Boc)-OH to Rink-Amide ChemMatrix resin Rink-Amide ChemMatrix resin (Biotage, 0.1 mmol) was weighed and placed in a disposable polypropylene solid-phase reaction tube for polypeptide synthesis. DMF (10 ml) was added and the resin was swollen under nitrogen bubbling for 10 min. DMF was removed under vacuum and DMF (10 ml) was added to wash the resin. This washing was repeated twice. Fmoc-L-Lys(Boc)-OH (1 mmol), 3-(diethoxyphosphyloxy)-1,2,3-benzotriazin-4-one (DEPBT) (1 mmol), and diisopropylethylamine (DIEA, 2 mmol) were weighed and dissolved in DMF (10 ml), and then loaded onto the swollen Rink-Amide ChemMatrix resin. The reaction was carried out at room temperature for 2 h with shaking. After the reaction was completed, the resin was washed twice with DMF and dichloromethane (DCM) alternately, and finally washed three times with DMF.

[0066] 3.1.2 Removal of Fmoc protecting group with Fmoc-L-Lys(Boc)-Rink-amide resin Piperidine / DMF (20%, 10 ml) was added to a solid-phase reaction tube containing Fmoc-L-Lys(Boc)-Rink Amide resin. The reaction was carried out at room temperature for 10 minutes with shaking. Next, piperidine / DMF (20%, 10 ml) was added, shaken at room temperature for 10 minutes, and then removed. After the reaction was complete, the resin was washed four times with DMF (10 ml).

[0067] 3.1.3 Conjugation of peptide chain sequences The peptide chain sequence of compound 1 is (H-His-Aib-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Val-Ser-Ser-Tyr-Leu-Glu-Glu-Glu-Ala-Ala-Lys-Glu-Phe-Ile-Ala-Trp-Leu-Val-Arg-Gly-Gly-Pro-Ser-Ser-Gly-Ala-Pro-Pro-Pro-Ser-Lys-NH2) from the amino to carboxy terminus. The amounts of amino acid derivatives and coupling reagents and their coupling methods were the same as those used to couple Fmoc-L-Lys(Boc)-OH to Rink-Amide ChemMatrix resin. The amino acid residues used in the synthesis were Fmoc-L-His(Trt)-OH, Fmoc-Aib-OH, Fmoc-L-Glu(OtBu)-OH, Fmoc-Gly-OH, Fmoc-L-Thr(tBu)-OH, Fmoc-L-Phe-OH, Fmoc-L-Ser(tBu)-OH, Fmoc-L-Asp(OtBu)-OH, Fmoc-L-Val-OH, Fmoc-Tyr(tBu)-OH, Fmoc-L-Ala-OH, Fmoc-L-Lys(Boc)-OH, Fmoc-L-Ile-OH, Fmoc-L-Trp(Boc)-OH, Fmoc-L-Leu-OH, Fmoc-L-Arg(Pbf)-OH, and Fmoc-L-Pro-OH. Condensation of the amino acid derivatives and Fmoc deprotection were repeated to finally obtain a resin peptide containing the polypeptide sequence of compound 1.

[0068] 3.1.4 Resin peptide splitting The resin peptide obtained from step 3 was washed three times successively with DMF and DCM, then dried under vacuum. Then, 10 ml of freshly prepared lysate (trifluoroacetic acid:triisopropylsilane:water=90:5:5, v:v:v) was added. The reaction was carried out at room temperature with shaking for 2 hours. After the reaction was completed, filtration was performed and the resin was washed twice with trifluoroacetic acid. The filtrate was pooled and then a large amount of frozen anhydrous isopropyl ether was added to precipitate the solid. After centrifugation, the supernatant was removed to obtain the crude polypeptide product of compound 1.

[0069] 3.1.5 Purification of crude peptides by reversed-phase liquid chromatography The crude peptide was dissolved in a mixed solvent containing 0.1% trifluoroacetic acid and 20% acetonitrile / water, filtered through a 0.22 μm membrane, and separated using a WATERS Prep150 LC reversed-phase high performance liquid chromatography system, buffer A (0.1% trifluoroacetic acid, 10% acetonitrile aqueous solution) and buffer B (0.1% trifluoroacetic acid, 90% acetonitrile aqueous solution). Wherein, the chromatography column was an X-SELECT OBD C-18 (WATERS) reversed-phase chromatography column. During the purification process, the detection wavelength of the chromatography was set to 220 nm, and the flow rate was 20 mL / min. The product-related fractions were collected and lyophilized to obtain a high-purity polypeptide product of compound 1 with a yield of 20%. The purity of the high-purity polypeptide product was measured and identified by analytical high performance liquid chromatography and liquid chromatography / mass spectrometry. Its purity was 95.38%, and the molecular weight of the compound was 4218.4.

[0070] 3.2 Chemical synthesis of compounds 2–24, 34–48, 63–73, and 78–80 According to the experimental scheme of compound 1, the polypeptide compounds numbered 2 to 24, 34 to 48, 63 to 73, and 78 to 80 of the present invention were synthesized, and the purity and molecular weight of these compounds were measured by analytical ultra-high performance liquid chromatography and liquid chromatography / mass spectrometry. Specifically, they are shown in Table 1 below. Table 1 JPEG0007577678000008.jpg202128JPEG0007577678000009.jpg54128

[0071] 3.3 Chemical synthesis of compound 25 conjugated with fatty acid 3.3.1 Conjugation of Fmoc-L-Lys(Mtt)-OH to Rink-Amide ChemMatrix resin Rink-Amide ChemMatrix resin (Biotage, 0.1 mmol) was weighed and placed in a disposable polypropylene solid-phase reaction tube for polypeptide synthesis. DMF (10 ml) was added and the resin was swollen under nitrogen bubbling for 10 min. DMF was removed under vacuum and DMF (10 ml) was added to wash the resin. This washing was repeated twice. Fmoc-L-Lys(Mtt)-OH (1 mmol), 3-(diethoxyphosphyloxy)-1,2,3-benzotriazin-4-one (DEPBT) (1 mmol), and diisopropylethylamine (DIEA, 2 mmol) were weighed and dissolved in DMF (10 ml), then loaded onto the swollen Rink-Amide ChemMatrix resin. The reaction was carried out at room temperature for 2 h with shaking. After the reaction was completed, the resin was washed twice with DMF and dichloromethane (DCM) alternately, and finally washed three times with DMF.

[0072] 3.3.2 Fmoc deprotection and peptide chain elongation Following the same synthesis method as in Example 1, Fmoc deprotection from Fmoc-L-Lys(Mtt)-Rink Amide ChemMatrix resin and subsequent peptide chain elongation were carried out to obtain the resin peptide containing compound 25, in which Boc-L-Tyr(t-Bu)-OH was used as the N-terminal amino acid residue.

[0073] 3.3.3 Mtt deprotection of resin peptide and modification of lysine side chain After the above peptide-resin elongation was completed, a mixture of hexafluoroisopropanol / dichloromethane (30%, 10 ml) was added, shaken, reacted at room temperature for 45 minutes, and then removed. Then, a mixture of hexafluoroisopropanol / dichloromethane (30%, 10 ml) was added again, shaken, reacted at room temperature for 45 minutes, and then removed. After the reaction was completed, the resin was washed six times with DMF. Other coupling / deprotection cycles using the Fmoc / tBu solid phase synthesis strategy to extend the side chain of lysine included Fmoc-NH-PEG2-COOH, Fmoc-L-Glu-OtBu, and HOOC-(CH2) 16 For all conjugations, reactions were carried out at room temperature, with 1 mmol of amino acid construct, 1 mmol of DEPBT, and 2 mmol of DIEA reacted in DMF for 4 h.

[0074] 3.3.4 Product separation and purification The resin peptide obtained in the above step was washed twice consecutively with DMF and DCM, and then dried under vacuum. Then, freshly prepared lysate (trifluoroacetic acid:triisopropylsilane:water=90:5:5, v:v:v) was added. The reaction was carried out at room temperature for 2 hours with shaking. After the reaction was completed, filtration was performed and the resin was washed twice with trifluoroacetic acid. The filtrate was pooled, and then a large amount of frozen anhydrous isopropyl ether was added to precipitate the solid. After centrifugation, the supernatant was removed to obtain the crude polypeptide product of compound 25.

[0075] 3.3.5 Purification of compound 25 by reversed-phase liquid chromatography The crude peptide was dissolved in a mixed solvent containing 0.1% trifluoroacetic acid and 20% acetonitrile / water, filtered through a 0.22 μm membrane, and separated using a WATERS Prep150 LC reversed-phase high performance liquid chromatography system, buffer A (0.1% trifluoroacetic acid, 10% acetonitrile in water) and buffer B (0.1% trifluoroacetic acid, 90% acetonitrile in water). Wherein, the chromatography column was an X-SELECT OBD C-18 reversed-phase chromatography column. During the purification process, the detection wavelength of the chromatography was set to 220 nm, and the flow rate was 20 mL / min. The product-related fractions were collected and lyophilized to obtain a high-purity polypeptide product of compound 25 with a yield of 18%. The purity and molecular weight of the high-purity polypeptide product were measured by analytical high performance liquid chromatography and liquid chromatography / mass spectrometry. Its purity was 96.23%, and the molecular weight of the compound was 5008.6.

[0076] 3.4 Chemical synthesis of compounds 26–33 and 49–62 According to the experimental scheme of compound 25, the polypeptide compounds of the present invention (compounds 26 to 33 and 49 to 62) were synthesized, and the purity and molecular weight of these compounds were measured by analytical high performance liquid chromatography and liquid chromatography / mass spectrometry. Specifically, they are shown in Table 2 below. Table 2 JPEG0007577678000010.jpg112123

[0077] 3.5 Chemical synthesis of compound 74 3.5.1 Conjugation of Fmoc-L-Lys(Mtt)-OH to Rink-Amide ChemMatrix resin Rink-Amide ChemMatrix resin (Biotage, 0.1 mmol) was weighed and placed in a disposable polypropylene solid-phase reaction tube for polypeptide synthesis. DMF (10 ml) was added and the resin was swollen under nitrogen bubbling for 10 min. DMF was removed under vacuum and DMF (10 ml) was added to wash the resin. This washing was repeated twice. Fmoc-L-Lys(Mtt)-OH (1 mmol), 3-(diethoxyphosphyloxy)-1,2,3-benzotriazin-4-one (DEPBT) (1 mmol), and diisopropylethylamine (DIEA, 2 mmol) were weighed and dissolved in DMF (10 ml), then loaded onto the swollen Rink-Amide ChemMatrix resin. The reaction was carried out at room temperature for 2 h with shaking. After the reaction was completed, the resin was washed twice with DMF and dichloromethane (DCM) alternately, and finally washed three times with DMF.

[0078] 3.5.2 Fmoc deprotection and peptide chain elongation Following the same synthesis method as in Example 1, Fmoc deprotection from Fmoc-L-Lys(Mtt)-Rink Amide ChemMatrix resin and subsequent peptide chain elongation were carried out to obtain the resin peptide containing compound 74, in which Boc-L-Tyr(t-Bu)-OH was used as the N-terminal amino acid residue.

[0079] 3.5.3 Mtt deprotection of resin peptides and modification of lysine side chains After the above peptide-resin elongation was completed, a mixture of hexafluoroisopropanol / dichloromethane (30%, 10 ml) was added, shaken, reacted at room temperature for 45 minutes, and then removed. Then, a mixture of hexafluoroisopropanol / dichloromethane (30%, 10 ml) was added again, shaken, reacted at room temperature for 45 minutes, and then removed. After the reaction was completed, the resin was washed six times with DMF. Other coupling / deprotection cycles using the Fmoc / tBu solid phase synthesis strategy to extend the side chain of lysine included Fmoc-NH-PEG2-COOH, Fmoc-L-Glu-OtBu, and HOOC-(CH2) 18-COOt-Bu. In all conjugation reactions, the reactions were carried out at room temperature, with 1 mmol of amino acid construct, 1 mmol of DEPBT, and 2 mmol of DIEA reacted in DMF for 4 h.

[0080] 3.5.4 Product separation and purification The resin peptide obtained in the above step was washed twice consecutively with DMF and DCM, and then dried under vacuum. Then, freshly prepared lysate (trifluoroacetic acid:triisopropylsilane:water=90:5:5, v:v:v) was added. The reaction was carried out at room temperature for 2 hours with shaking. After the reaction was completed, filtration was performed and the resin was washed twice with trifluoroacetic acid. The filtrate was pooled, and then a large amount of frozen anhydrous isopropyl ether was added to precipitate the solid. After centrifugation, the supernatant was removed to obtain the crude polypeptide product of compound 74.

[0081] 3.5.5 Purification of compound 74 by reversed-phase liquid chromatography The crude peptide was dissolved in a mixed solvent containing 0.1% trifluoroacetic acid and 20% acetonitrile / water, filtered through a 0.22 μm membrane, and separated using a WATERS Prep150 LC reversed-phase high performance liquid chromatography system, buffer A (0.1% trifluoroacetic acid, 10% acetonitrile in water) and buffer B (0.1% trifluoroacetic acid, 90% acetonitrile in water). Wherein, the chromatography column was an X-SELECT OBD C-18 reversed-phase chromatography column. During the purification process, the detection wavelength of the chromatography was set to 220 nm, and the flow rate was 20 mL / min. The product-related fractions were collected and lyophilized to obtain a high-purity polypeptide product of compound 74 with a yield of 18%. The purity and molecular weight of the high-purity polypeptide product were measured by analytical high performance liquid chromatography and liquid chromatography / mass spectrometry. Its purity was 95.14%, and the molecular weight of the compound was 5020.6.

[0082] 3.6 Chemical synthesis of compounds 75-77 and 81-83 According to the experimental scheme of compound 74, the polypeptide compounds of the present invention (compounds 75 to 77 and 81 to 83) were synthesized, and the purity and molecular weight of these compounds were measured by analytical high performance liquid chromatography and liquid chromatography / mass spectrometry. Specifically, they are shown in Table 3 below. Table 3 JPEG0007577678000011.jpg52158

[0083] Biological testing and evaluation The following test examples are provided to further illustrate the present invention, but are not intended to limit the scope of the invention.

[0084] 1. Experimental Reagents JPEG0007577678000012.jpg92142

[0085] 2. Experimental Apparatus JPEG0007577678000013.jpg64142

[0086] 3. Test Example 3.1. Evaluation of the Stimulating Activity of Test Compounds on the Glucagon-Like Peptide-1 Receptor (GLP-1R) 3.1.1 Experimental Objective: The purpose of this experiment is to measure the stimulatory activity of the numbered compounds on the glucagon-like peptide-1 receptor (GLP-1R).

[0087] 3.1.2 Experimental Method: Frozen CHO-K1 / GLP-1R / CRE-luc stably transfected cell line was removed from liquid nitrogen tank, quickly thawed in a 37°C water bath, and resuspended in DMEM / F12 medium (Gibco Cat. No. 11330032). After centrifugation, the cells were washed once and resuspended in experimental buffer (DMEM / F12 medium with 0.1% casein (Sigma Cat. No. C3400)) and cell density was adjusted with the experimental buffer. The cells were plated in a 384-well plate (Sigma Cat. No. CLS4514) at a density of 2500 cells / 5 μL / well, and then 2.5 μL of IBMX working solution (Sigma Cat. No. I7018, IBMX final concentration: 0.5 mM) prepared with buffer and 2.5 μL of gradient diluted polypeptide sample were added to each well, centrifuged at 1000 rpm for 1 min, shaken for 30 s to mix well, and incubated at room temperature for 30 min. Cisbio cAMP-Gs Dynamic Kit (Cisbio Cat. No. 62AM4PEC) was used for detection. cAMP-d2 and anti-cAMP-Eu 3+ -cryptate was diluted 20-fold with cAMP dissolution solution & detection buffer and mixed well. 5 μL of cAMP-d2 diluted solution was added to each well, followed by 5 μL of anti-cAMP-Eu 3+ -Cryptate dilutions were added to each well, mixed well by shaking for 30 seconds, and incubated in the dark at room temperature for 1 hour.

[0088] 3.1.3 Experimental data processing method: HTRF signals were read using a Biotek Synergy H1 microplate reader at an excitation wavelength of 320 nm and emission wavelengths of 620 and 665 nm. Signal ratios (665 nm / 620 nm × 10,000) were calculated and the signal ratios were nonlinearly fitted to sample concentrations with a four-parameter equation in GraphPad Prism 6 to obtain EC 50 The specific data are shown in Table 4 below.

[0089] 3.2 Evaluation of the Stimulatory Activity of Test Compounds on the Glucose-Dependent Insulinotropic Peptide Receptor (GIPR) 3.2.1 Experimental Objective: The purpose of this experiment is to measure the stimulatory activity of the numbered compounds on the glucose-dependent insulinotropic peptide receptor (GIPR).

[0090] 3.2.2 Experimental Method: Wild-type CHO-K1 cells were harvested, the cell suspension was adjusted to the appropriate density, plated in 6-well plates at 2 mL per well, and left in a 37°C, 5% CO2 incubator to allow attachment overnight. The transfection mixture (hGIPR plasmid, Fugene HD (Promega Cat. No. E2311), OptiMEM (Gibco Cat. No. 31985070)) was mixed thoroughly, left at room temperature for 15 minutes, and added to the corresponding cell wells at 100 μL. CHO-K1 cells were transfected for 24 hours, after which hGIPR was overexpressed on the cell surface. After transient transfection, the cells in the 6-well plate were harvested and washed once with experimental buffer (DMEM / F12 medium (Gibco Cat. No. 11330032) containing 0.1% casein (Sigma Cat. No. C3400), and the cell density was adjusted with the experimental buffer. The cells were plated in a 384-well plate (Sigma Cat. No. CLS4514) at a density of 5000 cells / 5 μL / well, and then 2.5 μL of IBMX working solution (Sigma Cat. No. I7018, IBMX final concentration: 0.5 mM) prepared with buffer and 2.5 μL of gradient diluted polypeptide sample were added to each well, centrifuged at 1000 rpm for 1 min, shaken for 30 s to mix well, and incubated at room temperature for 30 min. Cisbio cAMP-Gs Dynamic Kit (Cisbio Cat. No. 62AM4PEC) was used for detection. cAMP-d2 and anti-cAMP-Eu 3+ -cryptate was diluted 20-fold with cAMP dissolution solution & detection buffer and mixed well. 5 μL of cAMP-d2 diluted solution was added to each well, followed by 5 μL of anti-cAMP-Eu 3+ -Cryptate dilutions were added to each well, mixed well by shaking for 30 seconds, and incubated in the dark at room temperature for 1 hour.

[0091] 3.2.3 Experimental data processing method: HTRF signals were read using a Biotek Synergy H1 microplate reader at an excitation wavelength of 320 nm and emission wavelengths of 620 and 665 nm. Signal ratios (665 nm / 620 nm × 10,000) were calculated and the signal ratios were nonlinearly fitted to sample concentrations with a four-parameter equation in GraphPad Prism 6 to obtain EC 50 The specific data are shown in Table 4 below. Table 4. Stimulatory activity of polypeptide-based compounds against human GLP-1R and human GIPR receptors JPEG0007577678000014.jpg209129

[0092] Test conclusion: In the present invention, by designing and studying the polypeptide backbone / main chain, a compound with stronger stimulating activity than many GLP-1 / GIP receptor dual agonists in the field has been obtained, which may provide a better treatment for metabolic diseases. Table 5. Stimulatory activity of polypeptide compounds conjugated to fatty acids on human GLP-1R and human GIPR receptors. JPEG0007577678000015.jpg79140

[0093] Test conclusion: The present invention has found that the activity changes after conjugation to fatty acids of different peptide scaffolds are not the same, and that the peptide scaffolds of the present invention can maintain favorable activity at the GLP-1 and GIP receptors even after modification by conjugation to fatty acids.

[0094] 3.3 Polypeptide backbones conjugated to fatty acids and stability of polypeptide compounds Stability in plasma is very important for therapeutic polypeptide drugs because they are likely to be sensitive to polypeptide hydrolases and proteases in plasma: if the polypeptide is unstable in plasma, its half-life and efficacy will be affected.

[0095] 3.3.1 Purpose of the experiment: The purpose of this experiment is to investigate the stability of the numbered compounds in plasma.In order to compare the stability of the numbered compounds with those in the prior art, this experiment also tests the preferred polypeptide backbone compounds 023 (H23) and 024 (H24) and the preferred modified compound 089 (H89) taught in patent application WO2012 / 167744.

[0096] 3.3.2 Experimental Method: 5μL of samples with concentrations of 20, 50, 100, 200, 500, 1000, 2000, 5000, and 10000 ng / ml were added to 45μL of plasma from SD rats, and the content of the compounds was measured by LC-MS, and a standard calibration curve was prepared. 5μL of a polypeptide solution with a concentration of 1 mg / ml was added to 45μL of plasma from SD rats. Five samples were prepared for each test compound, and one sample was taken at 0 min, 30 min, 60 min, 120 min, and 240 min, respectively. The content of the remaining compounds was measured by LC-MS. The content at 0 min was used as the control (100%), and the relative content of the remaining compounds in the samples at other time points was calculated. The LC-MS method for detecting the compounds is as follows: 5% acetonitrile solution was prepared as solution A, and 95% acetonitrile solution was prepared as solution B. 15μL of the sample was injected at a flow rate of 0.6 ml / min. The time and solution ratios were as shown in the following table: The content of the compounds was measured on a Raptor Biphenyl 2.7 micron measuring column. JPEG0007577678000016.jpg66143

[0097] 3.3.3 Experimental Results: 1) The data on the stability of the polypeptide backbone in plasma obtained by the above experimental method are shown in Table 6. Table 6 JPEG0007577678000017.jpg43125

[0098] 3.3.4 Experimental Conclusions: Through research, it is found that the compound of the present invention can maintain stability in plasma (relative content>95%), indicating that the compound of the present invention has the potential to be a desirable drug and has favorable potential to treat diseases. The plasma stability of the compound of the present invention is superior to that of the compounds H23 and H24 in the prior art. 2) The data on the stability in plasma of the polypeptide conjugated to a fatty acid obtained by the above experimental method are shown in Table 7. Table 7 JPEG0007577678000018.jpg37125

[0099] Test conclusion: Compound 74 of the present invention has been found to be more stable (relative content >90%) in plasma at 4 hours than compound 75 and prior art compound H89.

[0100] 3.4 Pharmacokinetics of polypeptides conjugated to fatty acids in mice Plasma stability is one of the factors that affect the pharmacokinetics of polypeptide drugs, whose in vivo pharmacokinetics is also influenced by factors such as their absorption and clearance in the body.

[0101] 3.4.1 Experimental Objective: The objective of this experiment is to investigate the in vivo pharmacokinetics in mice (plasma) of the numbered compounds administered as a single dose by intravenous injection to Balb / c mice as test animals.

[0102] 3.4.2 Experimental Method: Male Balb / c mice (body weight 18-30 g, 7-9 weeks old) were purchased from Shanghai Jiesijie Laboratory Animal Co., Ltd. The numbered compounds were prepared in 20 mM citrate buffer (pH 7.0) and injected into the mice via the tail vein at a dose of 30 nmol per kg body weight. 0.2 ml of blood was collected at 0 h, 0.083 h, 0.25 h, 0.5 h, 1 h, 2 h, 4 h, 6 h, 8 h, 24 h, and 32 h. The collected mouse blood was centrifuged at 4°C and 6000 rpm for 6 minutes to separate plasma. The content of the numbered compounds in mouse plasma was measured according to the experimental method of Test Example 3.3.

[0103] 3.4.3 Experimental Results: Specific data obtained by the above experimental method is shown in Table 8. Table 8 JPEG0007577678000019.jpg22121

[0104] 3.4.4 Experimental Conclusions: Throughout the studies, the compounds of the present invention were found to have favorable pharmacokinetic properties in mice, indicating that they may have advantages in the treatment of disease.

[0105] Pharmacokinetics of polypeptides conjugated to 3.5 fatty acids in rats. 3.5.1 Experimental Objective: To further study the pharmacokinetics of the compounds of the present invention, this study examines the in vivo pharmacokinetics in rats (plasma) of the numbered compounds administered in a single dose by subcutaneous injection to SD rats as test animals.

[0106] 3.5.2 Experimental Method: Male SD rats (body weight 150-300 g) were purchased from Shanghai Jiesijie Laboratory Animal Co., Ltd. The numbered compounds were prepared in 20 mM citrate buffer (pH 7.0) and subcutaneously injected into the rats at a dose of 50 nmol per kg body weight. 0.2 ml of blood was collected at 0, 0.5, 1, 2, 4, 6, 8, 24, 32, 48, 72, 96, and 120 hours. The collected rat blood was centrifuged at 4°C and 6000 rpm for 6 minutes to separate plasma. The content of the numbered compounds in rat plasma was measured according to the experimental method of Test Example 3.3.

[0107] 3.5.3 Experimental Results: Specific data obtained by the above experimental method are shown in Table 9. Table 9 JPEG0007577678000020.jpg32136

[0108] 3.5.4 Experimental Conclusions: Through testing, compounds of the present invention were found to have favorable pharmacokinetic properties in rats, indicating that they may be of advantage in the treatment of disease.

[0109] 3.6 In vivo efficacy of polypeptides conjugated to fatty acids 3.6.1 Experimental Objective: The aim of this experiment was to investigate the glycemic effect of subcutaneous administration of the numbered compounds in diet-induced obese mice.

[0110] 3.6.2 Experimental Method: High-fat diet-induced obese C57BL / 6 mice (male, body weight 35-55 g, 10-12 weeks old) were purchased from Shanghai Jiesijie Laboratory Animal Co., Ltd. The diet-induced obese C57BL / 6 mice were subcutaneously injected with the numbered compounds (3 nmol / kg body weight), after which the mice were fasted but allowed to have water ad libitum. After 18 hours, 0.2 g / ml glucose solution was intraperitoneally injected at a dose of 2 g / kg body weight. According to the experimental design, blood was collected from the tails of the mice at 0, 15, 30, 60, and 120 minutes to measure blood glucose levels. Specifically, the mouse's body was fixed, the tail was exposed, the tip of the tail was cut, and the blood glucose level was measured by ACCU-CHEK Active (Roche). The area under the curve (AUC) of blood glucose levels was calculated based on the results at each time point.

[0111] 3.6.3 Experimental Results: Specific data obtained by the above experimental method is shown in Table 10. Table 10 JPEG0007577678000021.jpg21346

[0112] 3.6.4 Experimental Conclusions: In this experiment, the compound of the present invention showed a significant blood glucose lowering effect at a dose of 3 nmol / kg body weight, and the blood glucose AUC of the compound 74 group was reduced by 80% or more compared with the placebo group. The blood glucose AUC was significantly different from that of the prior art compounds H89 and semaglutide, which have GLP-1 activity.

Claims

1. A GLP-1 analogue or a pharma- ceutical acceptable salt thereof, said GLP-1 analogue having the general formula (I): X 1 -X 2 -Glu-Gly-Thr-Phe-Thr-Ser-Asp-X 10 -Ser-X 12 -Tyr-Leu-X 15 -X 16 -X 17 -X 18 -X 19 -X 20 -Glu-Phe-X 23 -X 24 -Trp-Leu-X 27 -X 28 -X 29 -X 30 -Pro-Ser-Ser-Gly-Ala-Pro-Pro-Pro-Ser-X 40 (I) During the ceremony, X 1 is selected from the amino acid residue Tyr; X2 is selected from the amino acid residue Aib; X 12 is selected from the amino acid residue He; X 15 is selected from the amino acid residue Glu; X 17 is selected from the amino acid residue He; X18 is selected from the amino acid residue Ala; X 10 is selected from the amino acid residues Val or Tyr; X 16 is selected from the amino acid residues Glu, Gly, Lys, or Aib; X 19 is selected from the amino acid residues Ala, Aib, or Gln; X20 is selected from the amino acid residues Gln, Glu, Lys, or Y1; X23 is selected from the amino acid residues Ile or Val; X24 is selected from the amino acid residues Ala, Asn, or Gln; X27 is selected from the amino acid residues Ile or Leu; X28 is selected from the amino acid residues Arg or Ala; X29 is selected from the amino acid residues Gly or Gln; X 30 is selected from the amino acid residues Gly, Lys, or Y1; X 40 is selected from the amino acid residues Lys or Y1 or is absent; Y1 is a Lys, Orn, Dap, Dab, or Cys residue whose side chain is conjugated to a substituent of formula {[2-(2-amino-ethoxy)-ethoxy]-acetyl}a-(γ-Glu)b-CO-(CH2)c-COOH; a is an integer from 1 to 3; b is an integer from 1 to 2; A GLP-1 analogue or a pharma- ceutically acceptable salt thereof, wherein c is an integer from 10 to 30.

2. R 1 -X 1 -X 2 -Glu-Gly-Thr-Phe-Thr-Ser-Asp-X 10 -Ser-X 12 -Tyr-Leu-X 15 -X 16 -X 17 -X 18 -X 19 -X 20 -Glu-Phe-X 23 -X 24 -Trp-Leu-X 27 -X 28 -X 29 -X 30 -Pro-Ser-Ser-Gly-Ala-Pro-Pro-Pro-Ser-X 40 -R 2 (II) (In the formula, R 1 is H, alkyl, acetyl, formyl, benzoyl, trifluoroacetyl, or pGlu; R 2 is -NH 2 or -OH; X 1 , X 2 , X 10 , X 12 , X 15 , X 16 , X 17 , X 18 , X 19 , X 20 , X 27 , X 28 , X 29 2. The GLP-1 analogue according to claim 1, or a pharma- ceutically acceptable salt thereof, wherein X 30 and X 40 are as defined in claim 1.

3. X 10 is selected from the amino acid residues Val or Tyr; X 16 is selected from the amino acid residues Glu, Gly, Lys, or Aib; X 19 is selected from the amino acid residues Ala, Aib, or Gln; X 20 is selected from the amino acid residues Gln, Glu, Lys, or Y1; X 23 is selected from the amino acid residues Ile or Val; X 24 is selected from the amino acid residues Ala, Asn, or Gln; X 27 is selected from the amino acid residues Ile or Leu; X 28 is selected from the amino acid residues Arg or Ala; X 29 is selected from the amino acid residues Gly or Gln; X 30 is selected from the amino acid residues Gly, Lys, or Y1; X 40 is selected from the amino acid residues Lys or Y1, or is absent; Y1 is a group having a side chain of the formula {[2-(2-amino-ethoxy)-ethoxy]-acetyl} a -(γ-Glu) b -CO-(CH 2 ) c a Lys, Orn, Dap, Dab, or Cys residue conjugated to a substituent represented by -COOH; a is an integer from 1 to 3; b is an integer from 1 to 2; The GLP-1 analogue or a pharma- ceutically acceptable salt thereof according to claim 1, wherein c is an integer of 10 to 30.

4. X 10 is selected from the amino acid residues Val or Tyr; X 16 is selected from the amino acid residues Glu, Gly, Lys, or Aib; X19 is selected from the amino acid residues Ala, Aib, or Gln; X 20 is selected from the amino acid residues Gln, Glu, Lys, or Y1; X 23 is selected from the amino acid residues Ile or Val; X 24 is selected from the amino acid residues Ala, Asn, or Gln; X 27 is selected from the amino acid residues Ile, or Leu; X 28 is selected from the amino acid residues Arg or Ala; X 29 is selected from the amino acid residues Gly or Gln; X 30 is selected from the amino acid residues Gly, Lys, or Y1; X 40 is selected from the amino acid residues Lys or Y1, or is absent; Y1 is a group having a side chain of the formula {[2-(2-amino-ethoxy)-ethoxy]-acetyl} a -(γ-Glu) b -CO-(CH 2 ) c a Lys or Cys residue conjugated to a substituent represented by -COOH; a is an integer from 1 to 3; b is an integer from 1 to 2; The GLP-1 analogue or a pharma- ceutically acceptable salt thereof according to claim 1, wherein c is an integer of 10 to 30. X10 is an amino acid residue Tyr; X16 is selected from the amino acid residues Glu, Lys, or Aib; X19 is selected from the amino acid residues Ala or Gln; X 20 is selected from the amino acid residues Gln, Lys, or Y1; X 23 is the amino acid residue Ile or Val; X 24 is selected from the amino acid residues Asn or Gln; X 27 is selected from the amino acid residue Leu; X 28 is selected from the amino acid residue Ala; X 29 is selected from the amino acid residues Gly or Gln; X 30 is selected from the amino acid residues Gly, Lys, or Y1; X 40 is selected from the amino acid residues Lys or Y1, or is absent; Y1 is a group having a side chain of the formula {[2-(2-amino-ethoxy)-ethoxy]-acetyl} a -(γ-Glu) b -CO-(CH 2 ) c a Lys, Orn, Dap, Dab, or Cys residue conjugated to a substituent represented by -COOH; a is an integer from 1 to 3; b is an integer from 1 to 2; The GLP-1 analogue or a pharma- ceutically acceptable salt thereof according to claim 1, wherein c is an integer of 10 to 30. X 10 is an amino acid residue Tyr; X 16 is the amino acid residue Glu or Lys; X19 is the amino acid residue Ala; X 20 is selected from the amino acid residues Gln, Lys, or Y1; X 23 is the amino acid residue Val; X 24 is the amino acid residue Asn; X 27 is the amino acid residue Leu; X 28 is the amino acid residue Ala; X 29 is the amino acid residue Gly or Gln; X 30 is selected from the amino acid residues Gly, Lys, or Y1; X 40 is selected from the amino acid residues Lys or Y1, or is absent; Y1 is a group having a side chain of the formula {[2-(2-amino-ethoxy)-ethoxy]-acetyl} a -(γ-Glu) b -CO-(CH 2 ) c a Lys, Orn, Dap, Dab, or Cys residue conjugated to a substituent represented by -COOH; a is an integer from 1 to 3; b is an integer from 1 to 2; The GLP-1 analogue or a pharma- ceutically acceptable salt thereof according to claim 1, wherein c is an integer of 10 to 30. X10 is an amino acid residue Tyr; X16 is the amino acid residue Lys; X19 is the amino acid residue Ala; X 20 is selected from the amino acid residues Gln or Lys; X 23 is the amino acid residue Val; X 24 is the amino acid residue Asn; X 27 is the amino acid residue Leu; X 28 is the amino acid residue Ala; X 29 is the amino acid residue Gly; X 30 is selected from the amino acid residues Gly, Lys, or Y1; X 40 is selected from the amino acid residues Lys or Y1, or is absent; Y1 is a group having a side chain of the formula {[2-(2-amino-ethoxy)-ethoxy]-acetyl} a -(γ-Glu) b -CO-(CH 2 ) c a Lys, Orn, Dap, Dab, or Cys residue conjugated to a substituent represented by -COOH; a is an integer from 1 to 3; b is an integer from 1 to 2; The GLP-1 analogue or a pharma- ceutically acceptable salt thereof according to claim 1, wherein c is an integer of 10 to 30. X10 is an amino acid residue Tyr; X16 is the amino acid residue Lys; X19 is the amino acid residue Ala; X 20 is selected from the amino acid residues Gln, Lys, or Y1; X 23 is the amino acid residue Val; X 24 is the amino acid residue Asn; X 27 is the amino acid residue Leu; X 28 is the amino acid residue Ala; X 29 is the amino acid residue Gly; X 30 is selected from the amino acid residues Gly or Lys; X 40 is selected from the amino acid residues Lys or Y1, or is absent; Y1 is a group having a side chain of the formula {[2-(2-amino-ethoxy)-ethoxy]-acetyl} a -(γ-Glu) b -CO-(CH 2 ) c a Lys, Orn, Dap, Dab, or Cys residue conjugated to a substituent represented by -COOH; a is an integer from 1 to 3; b is an integer from 1 to 2; The GLP-1 analogue or a pharma- ceutically acceptable salt thereof according to claim 1, wherein c is an integer of 10 to 30. X10 is an amino acid residue Tyr; X16 is the amino acid residue Lys; X19 is the amino acid residue Ala; X 20 is selected from the amino acid residues Gln, Lys, or Y1; X 23 is the amino acid residue Val; X 24 is the amino acid residue Asn; X 27 is the amino acid residue Leu; X 28 is the amino acid residue Ala; X 29 is the amino acid residue Gly; X 30 is selected from the amino acid residues Gly, Lys, or Y1; X 40 is selected from the amino acid residue Y1 or is absent; Y1 is a group having a side chain of the formula {[2-(2-amino-ethoxy)-ethoxy]-acetyl} a -(γ-Glu) b -CO-(CH 2 ) c a Lys, Orn, Dap, Dab, or Cys residue conjugated to a substituent represented by -COOH; a is an integer from 1 to 3; b is an integer from 1 to 2; The GLP-1 analogue or a pharma- ceutically acceptable salt thereof according to claim 1, wherein c is an integer of 10 to 30. X10 is an amino acid residue Tyr; X16 is the amino acid residue Lys; X19 is the amino acid residue Ala; X 20 is the amino acid residue Gln; X 23 is the amino acid residue Val; X 24 is the amino acid residue Asn; X 27 is the amino acid residue Leu; X 28 is the amino acid residue Ala; X 29 is the amino acid residue Gly; X 30 is selected from the amino acid residues Gly, Lys, or Y1; X 40 is selected from the amino acid residues Lys or Y1, or is absent; Y1 is a group having a side chain of the formula {[2-(2-amino-ethoxy)-ethoxy]-acetyl} a -(γ-Glu) b -CO-(CH 2 ) c a Lys, Orn, Dap, Dab, or Cys residue conjugated to a substituent represented by -COOH; a is an integer from 1 to 3; b is an integer from 1 to 2; The GLP-1 analogue or a pharma- ceutically acceptable salt thereof according to claim 1, wherein c is an integer of 10 to 30. X10 is an amino acid residue Tyr; X16 is the amino acid residue Lys; X19 is the amino acid residue Ala; X 20 is the amino acid residue Lys; X 23 is the amino acid residue Val; X 24 is the amino acid residue Asn; X 27 is the amino acid residue Leu; X 28 is the amino acid residue Ala; X 29 is the amino acid residue Gly; X 30 is selected from the amino acid residues Gly, Lys, or Y1; X 40 is selected from the amino acid residues Lys or Y1, or is absent; Y1 is a group having a side chain of the formula {[2-(2-amino-ethoxy)-ethoxy]-acetyl} a -(γ-Glu) b -CO-(CH 2 ) c a Lys, Orn, Dap, Dab, or Cys residue conjugated to a substituent represented by -COOH; a is an integer from 1 to 3; b is an integer from 1 to 2; The GLP-1 analogue or a pharma- ceutically acceptable salt thereof according to claim 1, wherein c is an integer of 10 to 30. X10 is an amino acid residue Tyr; X16 is the amino acid residue Lys; X19 is the amino acid residue Ala; X 20 is Y1; X 23 is the amino acid residue Val; X 24 is the amino acid residue Asn; X 27 is the amino acid residue Leu; X 28 is the amino acid residue Ala; X 29 is the amino acid residue Gly; X 30 is selected from the amino acid residues Gly, Lys, or Y1; X 40 is selected from the amino acid residues Lys or Y1, or is absent; Y1 is a group having a side chain of the formula {[2-(2-amino-ethoxy)-ethoxy]-acetyl} a -(γ-Glu) b -CO-(CH 2 ) c a Lys, Orn, Dap, Dab, or Cys residue conjugated to a substituent represented by -COOH; a is an integer from 1 to 3; b is an integer from 1 to 2; The GLP-1 analogue or a pharma- ceutically acceptable salt thereof according to claim 1, wherein c is an integer of 10 to 30.

13. X 10 is an amino acid residue Tyr; X16 is the amino acid residue Lys; X19 is the amino acid residue Ala; X 20 is Gln; X 23 is the amino acid residue Val; X 24 is the amino acid residue Asn; X 27 is the amino acid residue Leu; X 28 is the amino acid residue Ala; X 29 is the amino acid residue Gly; X 30 is selected from the amino acid residues Gly, Lys, or Y1; X 40 is selected from the amino acid residues Lys or Y1, or is absent; Y1 is a group having a side chain of the formula {[2-(2-amino-ethoxy)-ethoxy]-acetyl} a -(γ-Glu) b -CO-(CH 2 ) c a Lys residue conjugated to a substituent represented by -COOH; a is an integer from 1 to 3; b is an integer from 1 to 2; The GLP-1 analogue or a pharma- ceutically acceptable salt thereof according to claim 1, wherein c is an integer of 10 to 30.

14. X 27 The GLP-1 analogue or a pharma- ceutically acceptable salt thereof according to any one of claims 5 to 13, characterized in that the amino acid residue Ile can also be selected from the group consisting of aryl, aryl, phenyl ...

15. X 20 , X 30 , and X 40 are each independently selected from Y1; Y1 is a group having a side chain of the formula {[2-(2-amino-ethoxy)-ethoxy]-acetyl} a -(γ-Glu) b -CO-(CH 2 ) c a Lys, Orn, Dap, Dab, or Cys residue conjugated to a substituent represented by -COOH; a is an integer from 1 to 3; b is an integer from 1 to 2; 2. The GLP-1 analog or a pharma- ceutically acceptable salt thereof according to claim 1, wherein c is an integer from 10 to 30.

16. A GLP-1 analog or a pharma- ceutically acceptable salt thereof according to any one of claims 1 to 15, characterized in that, in the definition of Y1, a is 2; b is 1 or 2; and c is 16 to 20.

17. A GLP-1 analogue or a pharma- ceutically acceptable salt thereof according to any one of claims 1 to 15, characterized in that, in the definition of Y1, a is 2; b is 1 or 2; and c is 16, 18, or 20.

18. X 40 is selected from Y1; Y1 is a group having a side chain of the formula {[2-(2-amino-ethoxy)-ethoxy]-acetyl} a -(γ-Glu) b -CO-(CH 2 ) c a Lys residue conjugated to a substituent represented by -COOH; a is 2; b is 1 or 2; 16. The GLP-1 analogue or a pharma- ceutically acceptable salt thereof according to any one of claims 1 to 15, wherein c is 16 or 18.

19. 19. The GLP-1 analogue or a pharma- ceutically acceptable salt thereof according to any one of claims 1 to 18, characterized in that Y1 is covalently attached to the fatty acid by formation of an amide bond via the side chain amino group of Lys.

20. The GLP-1 analogue according to any one of claims 1 to 18, or a pharma- ceutically acceptable salt thereof, characterized in that Y1 is K(-OEG-OEG-γGlu-C18-OH) or K(-OEG-OEG-γGlu-C20-OH), represented by the chemical formula having the following structure:

21. 21. The GLP-1 analogue or a pharma- ceutically acceptable salt thereof according to any one of claims 1 to 20, characterized in that Y1 is covalently bound to the fatty acid via an amide bond via the ε-amino group of the C-terminal Lys.

22. A GLP-1 analogue of general formula (I) according to claim 1 or a pharma- ceutically acceptable salt thereof, characterized in that it is selected from the following compounds:

23. 1) a therapeutic amount of a GLP-1 analogue according to any one of claims 1 to 22 or a pharma- ceutical acceptable salt thereof, and 2) Pharmaceutically acceptable excipients or pharmaceutical carriers 13. A pharmaceutical composition comprising:

24. Use of a GLP-1 analogue according to any one of claims 1 to 22 or a pharma- ceutical acceptable salt thereof and a composition according to claim 23 in the manufacture of a medicament for treating non-insulin-dependent diabetes mellitus, insulin-dependent diabetes mellitus, or obesity.

25. 23. The GLP-1 analogue or a pharma- ceutically acceptable salt thereof according to any one of claims 1 to 22, administered simultaneously, separately or sequentially in combination with one or more agents selected from the group consisting of metformin, thiazolidinediones, sulfonylureas, dipeptidyl peptide hydrolase inhibitors, and sodium glucose transporters.

Citation Information

Patent Citations

  • Acylated GLP-1 compounds

    JP2008533105A

  • Glucagon / GLP-1 receptor coagonist

    JP2011524419A

  • GIP receptor-activated glucagon compounds

    JP2012530145A

  • Glucagon analogue exhibiting GIP receptor activity

    JP2014507402A

  • Incretin-insulin conjugate

    JP2017534676A